Bochot Amélie, Fattal Elias, Boutet Valérie, Deverre Jean Robert, Jeanny Jean Claude, Chacun Hélène, Couvreur Patrick
Laboratoire de Physico-Chimie, Pharmacotechnie, Biopharmacie, Unité Mixte de Recherche Centre National de la Recherche Scientifique 8612, Faculté de Pharmacie, Châtenay-Malabry, France.
Invest Ophthalmol Vis Sci. 2002 Jan;43(1):253-9.
The efficacy of sterically stabilized liposomes for delivering a model phosphodiester oligonucleotide intravitreally was investigated in the rabbit.
Ocular distribution and clearance from the vitreous humor of a model 16-mer oligothymidylate (pdT16) were evaluated in the rabbit by radioactivity measurements after intravitreal injection of either a solution or liposomes containing the [33P]pdT16 oligonucleotide. The integrity of pdT16 was investigated using a competitive hybridization assay.
The residual concentration of the [33P]pdT16 oligonucleotide within the ocular tissues was significantly increased after intravitreal administration of the liposomal suspension compared with a simple solution. Administration of liposome-encapsulated pdT16 oligonucleotide resulted in sustained release into the vitreous and the retina-choroid compared with release from the solution and in a reduced distribution to nontarget tissues (sclera, lens). In addition, liposomes protected the phosphodiester oligonucleotide against degradation. This was not observed after administration of the free oligonucleotide.
The intravitreal injection of a phosphodiester oligonucleotide encapsulated within liposomes is a new way of delivering intact oligonucleotide to the eye in a controlled manner. This offers interesting prospects for the treatment of retinal diseases.
在兔体内研究空间稳定脂质体玻璃体内递送模型磷酸二酯寡核苷酸的疗效。
通过放射性测量,在兔玻璃体内注射含[33P]pdT16寡核苷酸的溶液或脂质体后,评估模型16聚体寡胸苷酸(pdT16)在玻璃体液中的眼内分布和清除情况。使用竞争性杂交试验研究pdT16的完整性。
与单纯溶液相比,玻璃体内给予脂质体悬浮液后,眼组织内[33P]pdT16寡核苷酸的残留浓度显著增加。与溶液释放相比,脂质体包裹的pdT16寡核苷酸给药导致其在玻璃体和视网膜脉络膜中持续释放,并减少了向非靶组织(巩膜、晶状体)的分布。此外,脂质体保护磷酸二酯寡核苷酸不被降解。游离寡核苷酸给药后未观察到这种情况。
玻璃体内注射包裹在脂质体中的磷酸二酯寡核苷酸是一种以可控方式将完整寡核苷酸递送至眼内的新方法。这为视网膜疾病的治疗提供了有趣的前景。